Treatment of Hematomas Using a Synthetic Hybrid-Scale Fiber Matrix

Abstract

Effective treatment of traumatic subcutaneous hematomas is important to avoid complications, including skin necrosis, infection, scarring, hyperpigmentation, tissue edema, and prolonged recovery. Hematoma treatment may include evacuation followed by application of a skin substitute. Given the challenges associated with conventional skin substitutes, a fully-synthetic, resorbable, electrospun matrix composed of hybrid-scale fibers may offer a new option for treating hematomas. The present study reports on two clinical case reports assessing the use of the synthetic hybrid-scale fiber matrix for the treatment of hematomas.The hematomas located on the pretibial leg and dorsal foot were debrided in the operating room with evacuation of the hematomas, and the synthetic matrix was applied to the wounds. Following treatment, the wounds were observed for healing progress, including measuring and photographing the wounds and documenting clinical observations. The synthetic hybrid-scale fiber matrix was re-applied as needed based on clinician discretion.In both cases, treatment following the use of the synthetic hybrid-scale fiber matrix resulted in complete healing. Complete closure of all wounds was observed after two to three applications of the synthetic matrix within six to 16 weeks, and no adverse events were noted.In this study, hematomas of the foot and the leg demonstrated successful healing following treatment with the synthetic hybrid-scale fiber matrix. The successful clinical outcomes suggest that this biomaterial may offer benefits as part of a new treatment paradigm for hematomas and warrants further investigation.

Clinical Application of Bioresorbable, Synthetic, Electrospun Matrix in Wound Healing

“…A limited number of electrospun scaffold products have been successfully translated into human clinical use due to the challenges associated with commercialization, including the time and cost associated with product development under FDA design controls, implementation of commercial scale manufacturing, regulatory clearance activities and product distribution. Despite these challenges, recent work by our group has demonstrated the successful design and clinical translation of a novel electrospun hybrid-scale fiber matrix for use in wound management [17,[30][31][32][33][34][35][36][37][38][39][40][41][42][43][44]. Since receiving FDA clearance in 2017, this electrospun matrix has been utilized in multiple clinical and surgical settings and a variety of different wound types and clinical indications [30][31][32][33][34][35][36][37][38][39][40][41][42][43][44].…”

“…Despite these challenges, recent work by our group has demonstrated the successful design and clinical translation of a novel electrospun hybrid-scale fiber matrix for use in wound management [17,[30][31][32][33][34][35][36][37][38][39][40][41][42][43][44]. Since receiving FDA clearance in 2017, this electrospun matrix has been utilized in multiple clinical and surgical settings and a variety of different wound types and clinical indications [30][31][32][33][34][35][36][37][38][39][40][41][42][43][44]. The present review demonstrates the use of a synthetic hybrid-scale fiber matrix in clinical practice and offers collective insight into the efficacy and value of a hybrid-scale fiber matrix across multiple use cases in the wound care and soft tissue repair setting.…”

“…The positive healing response achieved in this study suggested that the synthetic hybrid-scale fiber matrix may provide the critical and needed solution for the chronic difficult-to-heal ulcers [37]. A retrospective case series of 9 patients with multiple severe co-morbidities was conducted at a single site [44]. The patients included in this study underwent amputations of the lower extremity.…”

“…Both hematomas were evacuated, and the synthetic hybrid-scale fiber matrix was fenestrated and applied to the wound bed. The average number of applications was 2.5 and both wounds achieved complete closure at an average of 11 weeks post-operatively [44].…”

Management of irradiated post-mastectomy wound dehiscence with synthetic electrospun fiber matrix: a case report

“…The results of a 2018 study showed that 85% of 82 chronic wounds of varying wound origins, such as non-healing (diabetic, venous leg, pressure) ulcers and traumatic, vascular, necrotic, and surgical wounds, healed within 12 weeks after initial treatment with the SEFM (13). Additionally, numerous studies have demonstrated successful SEFM treatment of closing complex surgical wounds to assist in secondary healing or stimulate the formation of granulation tissue necessary for staging reconstructive procedures, such as flaps or skin grafting (13)(14)(15)(16)(17)(18). However, there have been no documented clinical uses of an SEFM in irradiated tissue for enhanced wound healing.…”